Atopic Dermatitis
Conditions
Interventions
Prospective studies:The patient takes 100mg of Abrocitinib once daily and applies Crisaborole ointment twice daily for a duration of three months.
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Cross-sectional Study Inclusion Criteria (1) Diagnosis of atopic dermatitis. (2) No restrictions on nationality, gender, or ethnicity. (3) Willingness to cooperate in filling out clinical questionnaires. 2. Retrospective Study Inclusion Criteria (1) Patients who have already been treated with Abrocitinib tablets in combination with Crisaborole ointment for moderate-to-severe atopic dermatitis. (2) Treatment regimen: Oral Abrocitinib tablets 100mg daily combined with Crisaborole ointment twice daily. 3. Prospective Study Inclusion Criteria (1) Diagnosis of atopic dermatitis according to Hanifin-Rajka criteria, Williams criteria, or Zhang Jianzhong diagnostic criteria. (2) IGA score >=3, EASI score>=16, PP-PP-NRS score>=4, with severity classified as moderate-to-severe. (3) Patients who are currently receiving oral Abrocitinib tablets (100mg daily) combined with Crisaborole ointment (twice daily), or patients who are about to start this combination therapy.
Exclusion criteria
Exclusion criteria: 1. Cross-sectional Study Exclusion Criteria (1) Patients with critical illness, acute diseases, or severe mental disorders. (2) Patients with infections, pregnancy, childbirth, trauma, or other stress-related conditions. Patients with any systemic diseases or other active skin conditions that could affect the results of this study. 2. Retrospective Study Exclusion Criteria (1) History of using other JAK inhibitors. (2) Pregnancy, or history of hepatitis B, tuberculosis, HIV, or any chronic, opportunistic, or severe infections. 3. Prospective Study Exclusion Criteria (1) History of using other JAK inhibitors. (2) Pregnancy, or history of hepatitis B, tuberculosis, HIV, or any chronic, opportunistic, or severe infections.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eczema Area and Severity Index;Investigator's Global Assessment;Peak pruritus numerical score;Dermatology Life Quality Index;Dermoscopic image background color;Scale color in dermoscopic images;Vascular morphology under low-power dermatoscope;Vascular morphology under high magnification dermatoscope;Vascular arrangement pattern under dermatoscope;Other vascular arrangement patterns under dermatoscope, such as the centripetal shape of peripheral vascular loops and the circular arrangement around hair follicles;Skin Moisture;Skin oiliness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Transepidermal water loss;Skin elasticity;Skin pigmentation;Skin pH; | — |
Countries
China
Contacts
Public ContactBai Yanping
China-Japan Friendship Hospital
Outcome results
None listed